Browse the evidence

Limiting dietary fat and saturated fatty acids is an advised strategy for managing familial hypercholesterolemia.

Practitioners should advise FH patients to limit dietary fat and saturated fatty acids.

Supplementation of phytosterols and fiber can be helpful in managing familial hypercholesterolemia.

Practitioners may consider recommending phytosterol and fiber supplements to FH patients.

Patients with obesity experienced a median weight change of -5% at 6 months and -4% at 18 months after the intervention.

Practitioners can expect significant weight loss in patients with obesity following a multicomponent lifestyle intervention.

Patients reported increased participation in physical activities by +1 day/week after the intervention.

Encouraging physical activity is essential in lifestyle interventions for obesity.

Carbohydrate-restricted diets (CRDs) significantly improved glycemic control, including glucose (SMD = -2.94 mg/dL), insulin (SMD = -8.19 pmol/L), and HOMA-IR (-0.54).

Practitioners may consider CRDs as an effective strategy for improving glycemic control in adults.

LCDs and MCDs showed the most consistent metabolic benefits, particularly with combined fat and protein replacements.

Practitioners should consider LCDs and MCDs with mixed macronutrient replacements for optimal metabolic health.

Nutritional counseling and remote monitoring led to a statistically significant reduction in the average consumption of products containing fats and salt among overweight and obese women.

Practitioners can implement nutritional counseling and remote monitoring to effectively reduce fat and salt intake in overweight and obese patients.

The intervention resulted in a decrease in body weight, body mass index, waist circumference, blood pressure, and lipid metabolism parameters.

Health professionals can expect improvements in key health metrics when implementing similar interventions.

Dietary correction over 6 months contributed to the reduction of risk factors for cardiovascular diseases.

Dietary interventions can be effective in reducing cardiovascular disease risk factors in overweight and obese populations.

Weight loss interventions can improve reproductive outcomes in women.

Implementing weight loss strategies may enhance fertility treatment success.

Resistance training at both longer and shorter mean muscle lengths produces similar hypertrophic effects.

Practitioners can use a variety of muscle lengths in resistance training without significantly affecting hypertrophy outcomes.

Higher weekly set volumes produced a detectable advantage for muscle hypertrophy (1.8 cm²) but not maximal strength (3.48 kg).

Practitioners should consider higher training volumes for promoting muscle growth.

Sugar-sweetened beverage consumption is independently associated with noncommunicable diseases.

Reducing sugar-sweetened beverage consumption may help mitigate the risk of noncommunicable diseases.

Patients on dialysis achieved a mean total body weight loss of 7.8% (SD 6.1) after being prescribed semaglutide.

Semaglutide may be an effective weight loss intervention for patients on dialysis.

48.2% of patients who were ineligible for transplant due to elevated body mass index achieved waitlist activation after successful weight loss.

Successful weight loss with semaglutide can enhance transplant eligibility for patients.

GLP-1RAs promote weight loss and improve metabolic health.

GLP-1RAs can be utilized to aid in weight management and metabolic health improvement.

Phase 2 trials of retatrutide report unprecedented weight reductions comparable to bariatric surgery.

Retatrutide may provide an effective alternative to surgical weight loss methods.

Weight loss was consistently larger in the incretin intervention groups than in placebo or lifestyle intervention comparators.

Incretin therapies may be more effective for weight loss compared to lifestyle changes or placebo.

Semaglutide initiated 6 months post LSG results in significantly greater absolute weight loss of 14.03 ± 5.26 kg compared to 5.63 ± 6.25 kg in controls from 6 to 12 months post LSG (p < 0.0001).

Practitioners may consider semaglutide as an effective adjunct therapy for weight management in patients post-sleeve gastrectomy.

Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).

Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.

At 12 months, total weight loss was higher in the treatment group (35.77% ± 8.35%) compared to controls (28.37% ± 7.41%; p < 0.0001).

The findings support the use of semaglutide for improved long-term weight management post-surgery.

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).

Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.

Weight loss significantly explained heterogeneity in treatment effects on fibrosis improvement and MASH resolution.

Weight management should be emphasized in treatment plans for MASH to enhance treatment efficacy.